Supernus Pharmaceuticals (NASDAQ:SUPN) VP Sells $2,514,000.00 in Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh Bhatt sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $50.28, for a total transaction of $2,514,000.00. Following the transaction, the vice president directly owned 17,044 shares in the company, valued at approximately $856,972.32. This trade represents a 74.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ SUPN opened at $47.76 on Friday. Supernus Pharmaceuticals, Inc. has a 52-week low of $29.16 and a 52-week high of $59.68. The firm has a market capitalization of $2.75 billion, a price-to-earnings ratio of -70.23, a PEG ratio of 1.52 and a beta of 0.70. The stock has a 50 day moving average price of $51.11 and a 200 day moving average price of $49.19.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Craig Hallum set a $65.00 price target on Supernus Pharmaceuticals in a research note on Wednesday, February 25th. Zacks Research cut shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Thursday, January 29th. Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Monday, December 29th. Stifel Nicolaus upped their price target on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a “hold” rating in a research report on Friday, December 19th. Finally, Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Sunday, March 8th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $62.17.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Hantz Financial Services Inc. grew its stake in shares of Supernus Pharmaceuticals by 81.7% during the third quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock worth $30,000 after acquiring an additional 281 shares during the last quarter. Rockefeller Capital Management L.P. raised its position in shares of Supernus Pharmaceuticals by 354.8% in the 4th quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock valued at $42,000 after purchasing an additional 660 shares during the last quarter. Torren Management LLC acquired a new stake in Supernus Pharmaceuticals in the 4th quarter worth approximately $49,000. USA Financial Formulas acquired a new stake in Supernus Pharmaceuticals in the 3rd quarter worth approximately $50,000. Finally, EverSource Wealth Advisors LLC purchased a new stake in Supernus Pharmaceuticals during the 2nd quarter worth approximately $51,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.